Likelihood ratio Chi-squared | p-value | C statistic | |
1-year mortality | |||
Univariate analysis | |||
Pro-adrenomedullin | 24.38 | <0.001 | 0.715 |
BODE | 33.55 | <0.001 | 0.759 |
BOD# | 24.41 | <0.001 | 0.714 |
Multivariate analysis | |||
Pro-adrenomedullin plus: | |||
BODE | 53.33¶ | <0.001 | 0.829 |
BOD# | 46.82 | <0.001 | 0.815 |
2-year mortality | |||
Univariate analysis | |||
Pro-adrenomedullin | 26.98 | <0.001 | 0.663 |
BODE | 38.03 | <0.001 | 0.711 |
BOD# | 30.91 | <0.001 | 0.688 |
Multivariate analysis | |||
Pro-adrenomedullin plus: | |||
BODE | 59.46+ | <0.001 | 0.771 |
BOD# | 55.60 | <0.001 | 0.764 |
Analysed cohort n=594 (549 with all data available plus the 45 (88.2%) out of 51 patients with missing 6-min walk distance but available pro-adrenomedullin data). p-values compare variables with the null hypothesis. BODE: body mass, airflow obstruction, dyspnoea, exercise capacity index. #: BOD comprises BODE without the exercise capacity measurement; the three BOD components are scored according to the same cut-offs as they are in BODE [2], therefore, the “BOD index” ranges, in increasing severity, from 0 to 7. ¶: for 1-year mortality prediction in this sensitivity analysis, value added of pro-adrenomedullin with BODE Chi-squared 19.78, p<0.001. +: for 2-year mortality prediction in this sensitivity analysis, value added of pro-adrenomedullin with BODE Chi-squared 21.43, p<0.001.